Recent advances in the development of antimicrobial peptides against ESKAPE pathogens

Area of Science:

• Microbiology
• Infectious Diseases
• Drug Discovery

Background:

• Multi-drug resistant ESKAPE pathogens pose a significant global health threat, leading to increased mortality and healthcare costs.
• Existing antimicrobial treatments face limitations due to widespread resistance, necessitating novel therapeutic strategies.
• Antimicrobial peptides (AMPs), part of the innate immune system, exhibit broad-spectrum activity and potential as antibiotics.

Purpose of the Study:

• To review recent in vitro and in silico strategies for modifying antimicrobial peptides (AMPs).
• To explore methods for enhancing AMP stability and bioavailability for improved therapeutic applications.
• To discuss the potential of modified AMPs in preclinical settings against resistant pathogens.

Main Methods:

• Literature review of in vitro and in silico studies on antimicrobial peptide modification.
• Analysis of chemical modification strategies aimed at improving AMP stability and efficacy.
• Evaluation of preclinical data related to modified AMPs against resistant bacterial strains.

Main Results:

• Chemical modifications can significantly improve the stability and bioavailability of AMPs.
• In vitro and in silico approaches offer viable pathways for AMP optimization.
• Modified AMPs demonstrate potential for enhanced activity against multi-drug resistant pathogens.

Conclusions:

• Antimicrobial peptides represent a promising avenue for combating multi-drug resistant infections.
• Strategic chemical modifications are crucial for overcoming the limitations of natural AMPs.
• Further preclinical development of modified AMPs is warranted to address the ESKAPE pathogen threat.